NCT03904069View on ClinicalTrials.gov

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

March 13, 2023

Primary Completion Date

August 7, 2030

Study Completion Date

August 7, 2030

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

DRUG

AMG 553

AMG 553 is a chimeric antigen T-cell receptor (CAR-T) therapy

Trial Locations (3)

77030

MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

94305

Stanford University, Palo Alto

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY